Drug Trial Radar · NCT05683496
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Feb 14, 2023
Primary completion
May 26, 2025
Study completion May 26, 2025
Sponsor
- Lead sponsor
- ACELYRIN Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
Conditions
- Thyroid Eye Disease
Interventions
lonigutamabDrug
subcutaneous injection
PlaceboDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and characterization of nonserious treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 169
- Incidence and characterization of serious treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 169
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Research Site
Jacksonville, Florida
Clinical Research Site
Atlanta, Georgia
Clinical Research Site
Ann Arbor, Michigan
Clinical Research Site
East Setauket, New York
Clinical Research Site
New York, New York
Clinical Research Site
Morgantown, West Virginia
Clinical Research Site
Sydney, New South Wales, Australia
Clinical Research Site
Woolloongabba, Queensland, Australia
Clinical Research Site
Adelaide, South Australia, Australia
Clinical Research Site
East Melbourne, Victoria, Australia
Clinical Research Site
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.